Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent pancreatic cancer to be refractory to chemotherapy by using new tumor antigen KIF20A and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularizatio
Phase 1
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000002022
- Lead Sponsor
- Department of Gastroenterology, Juntendo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients have uncontrollable associated cancer. 2. Patients have uncontrollable severe infectional diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunotherapy during clinical trial. 5. Pregnancy or lactation. 6. Patients who have non-recovered injury. 7. Patients judged inappropriated by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method